Stem cell mobilization and transplantation represent pivotal advances in the management of multiple myeloma. This therapeutic approach involves stimulating the release of haematopoietic stem cells ...

A diagnosis of acquired von Willebrand disease and stage 2 multiple myeloma followed unusual symptoms, leading to extensive testing. Treatment included a four-drug chemotherapy regimen and an ...

Rapid advances have revolutionized the treatment of multiple myeloma, providing better disease control and prolonging survival. Patients are living years longer, thanks to novel combination therapies ...

A blood and marrow transplant (BMT) is a treatment used for certain cancer types that works by resetting the body’s ability to make healthy blood cells. It does this by replacing damaged or destroyed ...

Mansi Shah, MD, discusses the role of stem cell transplant in multiple myeloma (MM) and the logistical barriers to wider adoption of bispecific therapies. While chimeric antigen receptor (CAR) T-cell ...

The U.S. Food and Drug Administration (FDA) recently approved the use of Darzalex Faspro (daratumumab and hyaluronidase-fihj) ...

Hospitals are seeing success treating multiple myeloma with advanced therapies. Second autologous stem cell transplants, even ...

"Very few patients in earlier years underwent two stem cell transplants and survived long-term. Today, with newer drugs such as daratumumab, carfilzomib, and bispecific antibodies like teclistamab, we ...

REDWOOD CITY, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today announced the ...

Treatment of symptomatic patients with newly diagnosed multiple myeloma (MM) is dictated by risk-stratification and eligibility for hematopoietic cell transplantation (HCT). Progression-free survival ...

Please provide your email address to receive an email when new articles are posted on . The addition of subcutaneous daratumumab to triplet therapy improved outcomes in transplant-ineligible or ...